MannKind falls after quarterly revenue miss
07/05/2026 13:33
** Shares of drugmaker MannKind MNKD.O fall 6.7% to $3.32 premarket ** Company reports Q1 revenue of $90.2 million, missing analysts' average expectation of $106.6 million - data compiled by LSEG ** Says collaborations and services revenue decreased due to fewer units sold to partner United Therapeutics UTHR.O ** MNKD reports Q1 loss of 5 cents per share, compared with a 4-cent loss a year earlier ** Up to last close, shares down 37.2% this year (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children